On January 12, 2023, Bioventus Inc. was sued for violations of the federal securities laws in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"). An Amended Complaint was filed, amending the Class Period to February 11, 2021 to March 30, 2023.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.